SEC Form 10-K filed by ImmunityBio Inc.
$IBRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/12/2026 | $13.00 | Buy | BTIG Research |
| 5/20/2025 | $5.00 | Neutral → Overweight | Piper Sandler |
| 3/6/2025 | $8.00 | Buy | H.C. Wainwright |
| 1/10/2025 | $6.00 | Buy | BTIG Research |
| 5/12/2023 | $10.00 → $4.00 | Overweight → Neutral | Piper Sandler |
| 8/3/2022 | $8.00 | Buy | Jefferies |
4 - ImmunityBio, Inc. (0001326110) (Issuer)
4 - ImmunityBio, Inc. (0001326110) (Issuer)
4 - ImmunityBio, Inc. (0001326110) (Issuer)
DENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. Yet one of oncology's greatest challenges remains largely unsolved. Glioblastoma. Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with the difficulty of delivering therapies into the brain, has mad
Presentations highlight ANKTIVA®-based approaches in non-small cell lung cancer (NSCLC) and non-muscle invasive bladder cancer (NMIBC) ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced two poster presentations and one online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2, 2026, in Chicago. The presentations span two randomized Phase 3 trials in advanced NSCLC and a matched adjusted indirect comparison (MAIC) in BCG unresponsive non-muscle invasive bladder cancer (NMIBC), and collectively evaluate ANKTIVA® (nogapendekin alfa inbakicept-pmln), the company's IL-15 receptor agonist immunotherapy d
Issued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)Three drugs in human trials. A platform licensed from one of the world's top cancer-research universities. A market cap smaller than a Manhattan apartment. For investors willing to look where almost no one is looking, GT Biopharma is the kind of asymmetric setup that biotech is built on.NEW YORK, May 29, 2026 /CNW/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ:GTBP) carried a market capitalization of roughly $13 million. Thirteen million. That is not a typo, and it is not a shell company. It is a clinical-stage immuno-oncology company with three sep
8-K - ImmunityBio, Inc. (0001326110) (Filer)
10-Q - ImmunityBio, Inc. (0001326110) (Filer)
8-K - ImmunityBio, Inc. (0001326110) (Filer)
BTIG Research resumed coverage of ImmunityBio with a rating of Buy and set a new price target of $13.00
Piper Sandler upgraded ImmunityBio from Neutral to Overweight and set a new price target of $5.00
H.C. Wainwright initiated coverage of ImmunityBio with a rating of Buy and set a new price target of $8.00
Randomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026AACR and ASGCT presentations showcase durable survival and context-dependent iNKT activity in cancer and inflammatory lung diseaseNon-dilutive collaborations expand MiNK's platform and potentiate meaningful commercial revenue potential, while preserving focus on lead clinical programsCompany continues disciplined execution with reduced operating burn and focused advancement of high-priority programsNew clinical data to be presented at the ATS conference on May 20, 2026 NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, I
ImmunityBio, Inc. ((IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across the company's clinical trial pipeline, and to review financial results for the year ended December 31, 2025. Conference Call Details The conference call will begin at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Tuesday, March 3, 2026. Interested parties may access the conference call through our Investor Relations website, ir.immunitybio.com, under Company — Events & Presentations. Alternatively, individuals can access the call by dialing 1-844-539-3703 or 1-412-652-1273 (internationally).
Q3 2025 Revenue and Other Income Growth with Continued Strong Sales Momentum: $33.7 million of total revenue and other income, up from $26.4 million in Q2 2025. Product Revenue: Up 434% in Q3 2025 versus Q3 2024, with year-to-date sales of $74.7 million. ANKTIVA® Unit Growth: 467% unit sales volume growth in year-to-date 2025 compared to fiscal year 2024. Cash Position: $257.8 million in cash, cash equivalents, and marketable securities as of September 30, 2025, up from $153.7 million as of June 30, 2025. Glioblastoma: Early results from the first five recurrent glioblastoma patients treated with ANKTIVA plus the Optune Gio® device in combination with PD-L1 CAR-NK showed 100% disea
SC 13D/A - ImmunityBio, Inc. (0001326110) (Subject)
SC 13D/A - ImmunityBio, Inc. (0001326110) (Subject)
SC 13D/A - ImmunityBio, Inc. (0001326110) (Subject)
VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),
ImmunityBio, Inc. ((IBRX) announced today that its 2024 Annual Meeting of Stockholders will be held on Tuesday, June 11, 2024 at 9:30 a.m. Pacific Time. The Annual Meeting will be held in a virtual-only format and there will not be a physical location for the Annual Meeting. Stockholders of record at the close of business on April 17, 2024 are entitled to vote at and participate in the Annual Meeting. Richard Adcock, the Company's Chief Executive Officer and President, will provide a business update after the formal business of the Annual Meeting has ended. All interested parties are welcome to attend the Annual Meeting and listen to the Company update. Non-stockholders can attend the vir
- Yun Han named Chief Accounting Officer and Interim Chief Financial Officer - - Initial Funding Expected This Week Under $60 Million Financing Agreement - Faraday Future Intelligent Electric Inc. ("Faraday Future" or the "Company") (NASDAQ:FFIE), a California-based global shared intelligent electric mobility ecosystem company, today announced the appointment of Yun Han as Chief Accounting Officer and Interim Chief Financial Officer, effective October 25, 2022. Ms. Han replaces Becky Roof, who served as interim Chief Financial Officer until October 12, 2022, and is assisting the Company to ensure an orderly transition. This press release features multimedia. View the full release here: htt